VA

At the Precision Medicine World Conference this week, researchers discussed how they plan to return genomic results to participants of research-focused sequencing studies.

Cohort of Veterans

The Milwaukee Journal Sentinel writes that veterans are signing up for the Million Veteran Program.

The contract was awarded as part of the VA's Precision Oncology Program, which aims to provide advanced clinical care and generate cancer biomarker data.

The $12 million PRIME study will involve 2,000 veterans with major depressive disorder and 250 healthcare providers across 21 VA medical centers.

The company, which first signed on to provide services to the VA's Million Veteran Program in 2013, will provide the department with 34,000 more genomes.

The test analyzes clinically relevant genetic variants for 14 genes related to certain pain and mental health medication responses to help guide clinicians' prescribing decisions.

Advanced cancer patients at the VA will now have access to the company's blood-based PlasmaSelect 64 test as well as the CancerSelect 125 tissue test.

The partners have formed a public/private partnership to foster collaboration and data integration between different institutes researching brain trauma.

The VA has been steadily increasing its capacity to whole-genome sequence enrollees, and may now sequence as many as 30,000 individuals over the next two years.

The deal replaces an existing cancer testing contract to include PGDx's CancerSelect 125 test for pan-cancer tumor profiling.

Pages

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.